Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels
by Zacks Equity Research
Zacks.com featured highlights include: Insight, ConocoPhillips, Vale, Alexion and Archer Daniels
5 Stocks Trading Near 52-Week High With More Upside in Store
by Zacks Equity Research
Here are some stocks trading near their 52-week high levels with potential to scale higher.
Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up
by Zacks Equity Research
ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.
Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alexion beat both earnings and sales estimates in the second quarter of 2018.
Alexion Pharmaceuticals (ALXN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 22.49% and 6.55%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Drug Stocks to Report Earnings on Jul 26: AMGN, ALXN & More
by Zacks Equity Research
Let's see how these five pharma/biotech stocks are poised ahead of their scheduled results on Jul 26.
Is a Beat in Store for Alexion (ALXN) This Earnings Season?
by Zacks Equity Research
Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.
Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.
ALXN or RGNX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
ALXN vs. RGNX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
Karyopharm Initiates NDA Submission Process for Selinexor
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) initiates rolling submission of a New Drug Application to the FDA with a request for accelerated approval for selinexor.
J&J (JNJ) Faces $4.69 Billion Verdict in Talc Case (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families, who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
J&J's (JNJ) Phase III Study for Invokana Halted Earlier
by Zacks Equity Research
Johnson & Johnson's (JNJ) phase III CREDENCE study evaluating the efficacy and safety of its diabetes drug Invokana is being stopped early based on positive pre-specified efficacy data.
J&J's (JNJ) Q2 Earnings Beat on Higher Cancer Drug Sales
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2018. However, it narrows its full year sales forecast due to currency factors.
J&J (JNJ) Ordered to Pay $4.69 Billion in Talc Lawsuit (Revised)
by Zacks Equity Research
A Missouri jury asked Johnson & Johnson (JNJ) to pay $4.69 billion in damages to 22 women and their families who alleged that the company's baby powder contained asbestos that caused them to develop ovarian cancer.
Roche's Flu Drug Meets Primary Endpoint in Phase III Study
by Zacks Equity Research
Roche (RHHBY) announces that its antiviral candidate, baloxavir marboxil, met the primary endpoint in a phase III study in patients suffering from risk of complications from the flu.
Alexion Pharmaceuticals (ALXN): Moving Average Crossover Alert
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) is looking like an interesting pick from a technical perspective
Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
by Zacks Equity Research
FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.
Achillion's 3rd Factor D Inhibitor Enters Clinical Studies
by Zacks Equity Research
Achillion (ACHN) commences a first-in-human phase I study on ACH-5548, a next-generation, oral small-molecule factor D inhibitor.
ALXN vs. RGNX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. RGNX: Which Stock Is the Better Value Option?
Alexion (ALXN) Submits Application for ALXN1210 with FDA
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash
by Zacks Equity Research
The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.
Biotech Stock Roundup: AXON Soars, Amgen Drugs Get FDA, EC Nod
by Zacks Equity Research
Key areas of focus in the biotech space include regulatory approvals and licensing/acquisition deals.
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
by Zacks Equity Research
Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.